Imatinib
Accelerated Phase Chronic Myelogenous Leukemia
Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Accelerated Phase Chronic Myelogenous Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine University of Illinois at Chicago | Phase 2 | BBB |
Cyclophosphamide University of Illinois at Chicago | Phase 2 | BBB |
CYCLOSPORIN A University of Michigan Rogel Cancer Center | Phase 2 | BBB |
METHOTREXATE University of Michigan Rogel Cancer Center | Phase 2 | BB |
TACROLIMUS University of Michigan Rogel Cancer Center | Phase 2 | BB |
View all 46 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →